Driving global success in infectious disease prevention and treatment
The continued rise in difficult-to-treat infections and deaths caused by multidrug-resistant pathogens, as well as COVID-19 and its variants, reinforces the need to develop more safe, robust and effective therapies and vaccines against emerging and re-emerging diseases to protect people across the globe—particularly for those who have inadequate access to medical care.
Our infectious disease and vaccine leaders are among the more experienced and talented in the industry with deep knowledge in nonclinical development of products to prevent and treat bacterial, viral, fungal and parasitic infections. In fact, we've worked on well over 160 infectious disease and vaccine studies within the past five years and leverage this experience to shape new opportunities for you.
Decoding the complex challenges of vaccine and antimicrobial drug development
From selecting the most appropriate animal model system to acquiring information on the immunogenicity of vaccine antigens to determining characteristics critical to your vaccine’s success, we deliver quality data and insights to meet your timelines.
- Acquire validated stocks of well-characterized infectious challenge agents to evaluate prophylactic and therapeutic vaccines and antimicrobials
Capitalize on our significant BSL-1 and BSL-2 containment facilities, which are accredited by the American Association for Laboratory Animal Care, registered by the United States Department of Agriculture and assured by the Office of Laboratory Animal Welfare
Develop transport solutions and prepare custom minimal inhibitory concentration plates to test susceptibility for a new study drug
Comprehensive and integrated solutions to accelerate the development of your asset while maximizing your return on investment
- Réactifs d'anticorps personnalisés
- Analytique CFC
- Laboratoires centraux
- Biomarqueurs translationnels
- Solutions de gestion de laboratoire étendues
- Centre de solutions de biomarqueurs